Date: 2014-03-25
Type of information: Private placement
Company: Cellectis (France)
Investors: OrbiMed Advisors (USA), venBio (USA), Ridgeback Capital Management (USA), Aquilo Capital Management (USA), Merlin Nexus (USA)
Amount: €20.5 million
Funding type: private placement
Planned used: The proceeds of the transaction will be used for the acceleration of innovation in T cells genome engineering in order to provide them with new properties and the enhancement of the structures and function of antigenic chimeric receptor (CAR), and the self-developments of the company’s proprietary T cell CAR portfolio dedicated to the treatment of leukemia and solid tumors.
Others: * On March 25, 2014, Cellectis has announced it has received commitments for a capital increase of €20.52 million from U.S. biotechnology institutional investors. Cellectis will issue a total of 4,000,000 new shares at a price of €5.13 per share, above last closing sale price and at no discount to the 5-day VWAP. The financing was led by OrbiMed Advisors and included venBio, Ridgeback Capital Management, Aquilo Capital Management and Merlin Nexus, among others.
The capital increase was carried out without preferential subscription rights for the benefit of investors defined in article L.411-2 II of the French monetary and financial code (qualified investors and/or small circle of investors), in accordance with article L. 225-136 of the French commercial code and with the 11th resolution of Cellectis’s general meeting of shareholders held on June 14, 2013. The capital increase represents approximately 19% of the capital of the Company to date and a dilution to existing shareholders of approximately 16%. The settlement of the new shares shall take place (subject to usual market conditions) no later than the early days of April. The new shares, with a nominal value of € 0.05, will be common shares and will be listed on the same line as the existing of the company under ISIN code FR0010425595. They will carry the same dividend rights as the existing shares and will be entitled, after issuance, to all dividends declared by the company from that date.
Therapeutic area: Cancer - Oncology
